You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for NGB 2904
NGB 2904 is a potent and selective dopamine D3 receptor antagonist (Ki values are 1.4, 217, 223, 642, > 5000, > 10000 and > 10000 nM for D3, D2, 5-HT2, α1, D4, D1 and D5 receptors respectively). Potently antagonizes quinpirole-stimulated mitogenesis (IC50 = 6.8 nM). Attenuates cocaine's rewarding effects and inhibits relapse to drug-seeking behavior.
Compound Libraries for NGB 2904
Technical Data for NGB 2904
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for NGB 2904
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for NGB 2904
The following data is based on the product molecular weight 530.92. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||7.53 mL||37.67 mL||75.34 mL|
|1.25 mM||1.51 mL||7.53 mL||15.07 mL|
|2.5 mM||0.75 mL||3.77 mL||7.53 mL|
|12.5 mM||0.15 mL||0.75 mL||1.51 mL|
References for NGB 2904
References are publications that support the biological activity of the product.
Yuan et al (1998) NGB 2904 and NGB 2849: two highly selective DA D3 receptor antagonists. Bioorg.Med.Chem.Lett. 8 2715 PMID: 9873609
Xi et al (2006) The novel DA D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31 1393 PMID: 16205781
Pritchard et al (2007) The DA D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol.Biochem.Behav. 86 718 PMID: 17408730
If you know of a relevant reference for NGB 2904, please let us know.
View Related Products by Product Action
Keywords: NGB 2904, NGB 2904 supplier, Potent, selective, D3, antagonists, Dopamine, Receptors, dopaminergic, NGB2904, 2635, Tocris Bioscience
1 Citation for NGB 2904
Citations are publications that use Tocris products. Selected citations for NGB 2904 include:
Axel et al (2010) Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and DA D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 35 1464 PMID: 20200509
Do you know of a great paper that uses NGB 2904 from Tocris? Please let us know.
Reviews for NGB 2904
There are currently no reviews for this product. Be the first to review NGB 2904 and earn rewards!
Have you used NGB 2904?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.